https://markets.businessinsider.com/news/stocks/rezolute-provides-update-on-phase-3-sunrize-study-on-ersodetug-1034309210
Rezolute provides update on Phase 3 sunRIZE study on ersodetug | Markets Insider
Rezolute (RZLT) announced outcomes from an independent Data Monitoring Committee, DMC, review of the open label arm, OLA, portion of the sunRIZE...
providesupdatephase
https://rezolutebio.com/
Rezolute | Hypoglycemia & Hyperinsulinism | Ersodetug
Jan 13, 2026 - Rezolute is a rare disease company focused on developing ersodetug, a potential treatment for hypoglycemia caused by congenital and tumor hyperinsulinism.
hypoglycemiahyperinsulinismersodetug